Equities

Kintor Pharmaceutical Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Kintor Pharmaceutical Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)2.79
  • Today's Change0.00 / 0.00%
  • Shares traded956.00k
  • 1 Year change+196.81%
  • Beta0.5189
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Kintor Pharmaceutical Ltd is an investment holding company primarily engaged in the research and development of innovative medicine products. The Company's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The Company has two core drugs in the dermatology field, KX-826 and GT20029. The Company's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.

  • Revenue in HKD (TTM)12.44m
  • Net income in HKD-189.22m
  • Incorporated2018
  • Employees136.00
  • Location
    Kintor Pharmaceutical LtdNo. 20 Songbei RoadSuzhou Industrial ParkSUZHOU 215123ChinaCHN
  • Phone+86 51 262639909
  • Websitehttps://www.kintor.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sirnaomics Ltd13.90m-109.55m768.78m52.00------55.32-1.33-1.330.161-0.38040.0637----201,403.60-36.30-80.21-216.85-100.4967.44---570.30-27,838.86---8.20--------34.70---38.10--
JW (Cayman) Therapeutics Co Ltd201.32m-699.51m941.23m292.00--0.9141--4.68-1.69-1.690.48522.470.10461.349.59716,429.40-36.34-35.14-47.41-39.0655.52---347.47-898.771.45-1,808.420.2907---8.99--23.10---32.98--
Sunho Biologics Inc0.00-92.97m1.00bn128.00--1.84-----0.616-0.6160.003.480.00----0.00-14.33---15.84----------6.57--0.1242------39.74------
B&K Corp Ltd295.61k-206.83m1.09bn100.00--11.43--3,701.60-1.76-1.760.00250.8138----------------92.34---69,968.59------0.0371---44.70---101.78------
Brii Biosciences Ltd0.00-425.51m1.13bn96.00--0.3986-----0.5846-0.58460.003.910.00----0.00-14.05-49.92-14.09-54.57-------12,750.27----0.003---100.00---190.66---33.13--
Kintor Pharmaceutical Ltd12.44m-189.22m1.39bn136.00--5.10--111.83-0.4375-0.43750.02880.54670.019410.661.0674,049.78-29.53-47.72-44.54-55.96-55.12-36.16-1,521.00-8,974.730.4222-33.760.2881------85.36---53.11--
Wuhan YZY Biopharma Co Ltd164.23m-88.38m1.40bn106.00------8.55-0.4559-0.45590.8472-0.16040.580511.5413.961,453,323.00-31.24---133.35--63.96---53.82--0.9019-24.381.21------49.09------
HighTide Therapeutics Inc0.00-329.76m1.49bn57.00--3.75-----0.7294-0.72940.000.69420.00----0.00-49.50---63.55--------------0.2129------59.35------
Immunotech Biopharm Ltd0.00-253.13m1.60bn173.00---------0.4523-0.45230.00-0.28820.00----0.00-37.04-36.20-186.73-45.67--------0.0712-6.631.48------44.18--5.95--
Cloudbreak Pharma Inc78.16m-326.97m1.91bn60.00------24.47-0.3898-0.38980.0932-3.08------1,532,549.00-------------418.33------19.44------23.40------
ImmuneOnco Biopharmaceuticls Shanghi Inc126.96m-342.81m1.98bn195.00--3.08--15.57-0.8715-0.87150.32251.490.148--3,865.48813,859.90-40.09---51.56-------270.79------0.2236--19,109.59--16.76------
Data as of Feb 13 2026. Currency figures normalised to Kintor Pharmaceutical Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.31%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 08 Jan 20261.19m0.24%
SSgA Funds Management, Inc.as of 08 Jan 2026372.00k0.08%
DFA Australia Ltd.as of 30 Nov 20251.10k0.00%
GF Fund Management Co., Ltd.as of 30 Jun 20250.000.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.